ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

JANX vs MNKD // ALTMAN Z-SCORE & DEBT/EQUITY

Janux Therapeutics Inc. (NASDAQ) VS. MannKind Corporation (NASDAQ) • 15-METRIC TALLY: JANX 0 — MNKD 5
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (JANX VS. MNKD) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC JANX MNKD SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 92.30% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -13.80% 54.50% -68.30 MNKD /roic <GO>
EV/EBITDA & P/E Valuation — 24.6x — TIE /valuation <GO>
Free Cash Flow Yield -7.64% 1.22% -8.86 MNKD /fcf-yield <GO>
Operating Margin — 11.10% — TIE /operating-margins <GO>
Net Profit Margin — 1.70% — TIE /net-margins <GO>
Revenue Growth (YoY) — 22.20% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity ACTIVE — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 7/9 -5.00 MNKD /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 51.4 55.6 -4.20 MNKD /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.07B $1.13B -$57.3M MNKD /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR JANX REV MNKD REV JANX GROSS % MNKD GROSS % JANX FCF MNKD FCF
FY 2025 $441.5M $349.0M — 92.3% -$83.3M $13.7M
FY 2024 $276.8M $285.5M — 93.9% -$44.2M $32.8M
FY 2023 $204.3M $199.0M — — -$50.6M $34.1M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
JANX // BETA —
MNKD // BETA —